CybernaX attends BIO International Convention 2025 in Boston
16 June 2025 — CybernaX attended the BIO International Convention 2025 at the Boston Convention & Exhibition Center, taking part in the one-to-one partnering program. BIO is the largest and most heavily attended partnering event in the industry, drawing more than twenty thousand delegates from pharma, biotech, venture capital and regulatory affairs.
Dr. Zhefan Yuan, Chief Scientific Officer and Co-Founder, and Dr. Pengbo Guo, Chief Business Officer, were on site to present the CybernaX platform and to meet potential partners. Conversations centered on the areas where the company’s proprietary position is strongest: high-dose systemic delivery, tissue-specific targeting, and delivery by inhalation — each supported by freedom-to-operate work that lets partners build without inheriting somebody else’s IP problem.
The team met with global pharmaceutical companies and research institutions on co-development, technology licensing and commercialization, and with investors interested in the translation of non-viral delivery technology. Alongside its partnered work, CybernaX continues to advance an internal inhalable LNP program for pulmonary disease.
If you would like to continue a conversation that started at BIO, or begin one, we are always reachable at info@cybernaxbio.com.
About CybernaX
CybernaX Biotechnologies develops non-viral nucleic acid delivery technology, built on two lipid platforms: ELITE (CX Ionizable Lipid), an embodied-AI screened ionizable lipid library, and ENDURE (CX Stabilizing Lipid), a PEG-free monodisperse lipid built for long-term repeat dosing. The company licenses and co-develops its lipid platforms with biopharmaceutical and biotechnology partners worldwide.